- Advertise
- OLE Scientific Interchange Workshops
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Sarah Cannon | Strategic Alliance Partners
Latest from Sarah Cannon
Agents Targeting MET, RET, and Previously “Undruggable” KRAS Advance Treatment in NSCLC
March 11, 2021
Article
Melissa L. Johnson, MD, discusses the implications of recent advances made in the development of oncogenetargeted agents in non–small cell lung cancer.
Novel CDH6-Targeted ADC DS-6000 Enters the Pipeline in RCC and Ovarian Cancer
February 23, 2021
Article
February 23, 2021 - The first patient in a first-in-human phase 1 study has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate.
Lack of Concordance Regarding Plasma Testing in Lung Cancer Must Be Overcome
February 16, 2021
Article
Andrew Mckenzie, PhD, discusses the differences between tissue- and plasma-based NGS tests, factors that can lead to a lack of concordance, and important areas of ongoing research.
Dr. Spigel Discusses Advances in Early-Stage Lung Cancer
February 01, 2021
Video
David Spigel, MD, discusses advances in early-stage lung cancer treatment.
Dr. McKenzie on the Rationale for Concurrent Tissue and Liquid Biopsies in Lung Cancer
February 01, 2021
Video
Andrew McKenzie, PhD, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.
Assessing the Advantages of Adjuvant Targeted Therapy in Lung Cancer
January 25, 2021
Article
David Spigel, MD, discusses the future of adjuvant targeted therapy in lung cancer.